NCT06882148Recruiting
Drug Survival of Target Therapies in Atopic Dermatitis
Evaluation of Drug Survival of Target Therapies in Atopic Dermatitis
Source: ClinicalTrials.gov · Last updated 18 Mar 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This is an observational study with drug to evaluate the drug survival of approved target therapies in atopic dermatitis. Patients affected by moderate-severe atopic dermatitis who will start therapy with approved target drugs (dupilumab, tralokinumab, upadacitinib, abrocitinib, baricitinib) for AD will be enrolled. Patients already on therapy with these drugs will also be included. During the baseline and follow up visits, clinical and demographic data will be collected, according to ordinary clinical practice. Current or retrospective disease severity scores will also be collected. Among the main: Eczema Area and Severity Index (EASI), Investigator's Global Assessment (IGA), Dermatology Life Quality Index (DLQI), Pruritus Numerical Rating Scale (NRS pruritus), Sleep Numerical Rating Scale (NRS sleep), Patient Oriented Eczema Measure (POEM).
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 1167 (estimated)
- First submitted
- 10 Oct 2023
- Start date
- 12 Oct 2023
- Primary completion date
- 30 Oct 2026
- Lead sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Diseases
- Atopic dermatitis (eczema)
- NCT number
- NCT06882148
What you commit to
- Study type: Observational
- Planned participants: 1167
- From 12 Oct 2023 to the primary completion date, 30 Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have undergone systemic therapy with a biological drug or small molecules for whom the start date of treatment is not available and/or no clinical-demographic data were collected at baseline and at follow-up visits.
Age
- Patients under 18 years of age
Other
- Absence of informed consent to the study and processing of personal data for research purposes.
Who the study is looking for
- Age 18 years or older
- Diagnosed with moderate-to-severe atopic dermatitis (EASI\>24)
- Undergoing therapy (retrospective cohort) or undertaking systemic therapy with a biological drug or small molecules
- (for retrospective data) presence of at least one follow-up visit after the start of treatment for which clinical and demographic data were collected at baseline and follow-up visits.
- Signature of informed consent to the study and to the processing of personal data for the research
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS Coordinator of this site? Confirm its status | Rome | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.